<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094340</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AG034155-01</org_study_id>
    <nct_id>NCT01094340</nct_id>
  </id_info>
  <brief_title>Thalidomide for Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>&quot;Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banner Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of
      thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with
      mild to moderate Alzheimer's disease. This study will evaluate the effects of 24 weeks of
      treatment with Thalidomide on plasma biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A lumbar puncture will be done before treatment (baseline), and at 24 weeks to collect CSF
      for the quantification of biomarkers. As an exploratory effort, we will test the effects of
      thalidomide on the same biomarkers in the plasma and will determine if detectable changes
      mirror changes observed in the CSF.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improve cognition</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Thalidoide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>fixed dose over 8 clinic visits</description>
    <arm_group_label>Thalidoide</arm_group_label>
    <other_name>Celegene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a screening diagnosis of Probable Alzheimer's disease according to
             National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's
             Disease and Related Disorders Association (NINCDS/ADRDA) criteria.

          -  Subjects must have a Mini-Mental State Examination (MMSE) score of 12-26

          -  Subject must live at home.

          -  Must have a caregiver to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Liebsack, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Banner Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Sabbagh, MD</last_name>
      <phone>623-832-6500</phone>
      <email>marwan.sabbagh@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Marwan N Sabbagh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.shri.org</url>
    <description>Banner Sun Health Research Institute Website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Banner Health</investigator_affiliation>
    <investigator_full_name>Brian Browne</investigator_full_name>
    <investigator_title>MARWAN SABBAGH, MD Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

